Akums Drugs (AKUMS) | Stock Overview & Key Data
Akums Drugs Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: ₹1,175.90 on August 19, 2024
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Quarter Income Flow
Jun 30, 2025
Annual Income Flow
2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Akums Drugs
AKUMS
|
82.60B Mid-cap | 0.97% | -3.34% | 15.68% | 28.42% | 21.20% | -8.21% | -34.69% | -34.69% | -34.69% | -34.69% | -34.69% |
|
Sun Pharmaceutical
SUNPHARMA
|
3.88T Large-cap | -3.03% | -1.92% | 2.17% | -1.01% | 3.92% | 7.25% | 79.99% | 166.96% | 144.01% | 669.48% | 2,278.32% |
|
Divi's Laboratories
DIVISLAB
|
1.69T Large-cap | -3.25% | -0.65% | 4.12% | 1.88% | 3.66% | 0.83% | 89.86% | 56.44% | 484.44% | 1,625.50% | 9,907.51% |
|
Piramal Pharma
PPLPHARMA
|
199.68B Mid-cap | -4.15% | 4.19% | 9.65% | -8.26% | -1.69% | -16.24% | 115.91% | 3.17% | 3.17% | 3.17% | 3.17% |
|
Eris Lifesciences
ERIS
|
193.36B Mid-cap | 3.43% | 3.21% | 2.87% | -10.51% | -6.95% | -11.56% | 119.21% | 94.70% | 132.59% | 132.59% | 132.59% |
|
Neuland Laboratories
NEULANDLAB
|
184.81B Mid-cap | 1.31% | 5.38% | 33.00% | 0.11% | 12.83% | 48.55% | 510.11% | 716.28% | 2,058.53% | 16,354.50% | 19,900.00% |
Ownership & Short Interest
Calculate Your Akums Drugs Investment Returns
Long-Term Investment Performance Analysis
Akums Drugs stock price in Aug 2024 was ₹803.15, A ₹1,000.00 lump sum investment in Akums Drugs made 1 years ago would be worth approximately ₹691.65 today, representing a negative return of -30.83%. This translates to an annualized return (CAGR) of -18.26%.
1 Year 9 Months Investment Scenario (Aug 2024 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is AKUMS's 52-week high and low?
- In the last 52 weeks, Akums Drugs reached a high of ₹597.00 (on June 27, 2025) and a low of ₹409.30 (on January 21, 2026).
- What is the market cap and P/E ratio for AKUMS?
- Curious about Akums Drugs's size and valuation? Its market capitalization stands at 82.60B. When it comes to valuation, the P/E ratio (trailing twelve months) is 25.39, and the forward P/E (looking ahead) is 21.47.
- Does AKUMS pay dividends? If so, what's the yield?
- As for dividends, Akums Drugs isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Akums Drugs's main competitors or similar companies to consider before investing?
When looking at Akums Drugs, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sun Pharmaceutical
SUNPHARMA3.88T Healthcare Drug Manufacturers - Specialty & Generic 7.25% 79.99% Divi's Laboratories
DIVISLAB1.69T Healthcare Drug Manufacturers - Specialty & Generic 0.83% 89.86% Piramal Pharma
PPLPHARMA199.68B Healthcare Drug Manufacturers - Specialty & Generic -16.24% 115.91% Eris Lifesciences
ERIS193.36B Healthcare Drug Manufacturers - Specialty & Generic -11.56% 119.21% Neuland Laboratories
NEULANDLAB184.81B Healthcare Drug Manufacturers - Specialty & Generic 48.55% 510.11% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Akums Drugs & Pharmaceuticals Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Akums Drugs's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 11.04%, the Debt to Equity ratio from the most recent quarter is 2.85, and its Gross Profit Margin stands at 41.48%.
- What is the recent revenue and earnings growth for AKUMS?
- Looking at Akums Drugs's growth, its revenue over the trailing twelve months (TTM) was INR43B. Compared to the same quarter last year (YoY), quarterly revenue grew by 14.80%, and quarterly earnings saw a YoY growth of 1.70%.
- How much of AKUMS stock is held by insiders and institutions?
- Wondering who owns Akums Drugs stock? Company insiders (like executives and directors) hold about 80.17% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 13.60%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.